Shares of Acadia Pharmaceuticals (ACAD) gained over 15% on June 15 to close at $18.77 after the Food and Drug Administration (FDA) posted briefing documents for pimavanserin for treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP). Headquartered in California, Acadia Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of small-molecule drugs that address unmet medical needs in central nervous system disorders. Details The company's lead candidate, NUPLAZID (pimavanserin), is aimed at the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is under phase 3 development for the treatment of Alzheimer’s disease psychosis and negative symptoms of schizophrenia.
https://www.tipranks.com/news/why-did-acadia-pharmaceuticals-shares-gain-15?utm_source=advfn.com&utm_medium=referral
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Oct 2022 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Nov 2021 to Nov 2022 Click Here for more Acadia Pharmaceuticals Charts.